An open-label, randomized phase II trial of personalized peptide vaccination in patients with bladder cancer that progressed after platinum-based chemotherapy

Clinical Cancer Research

Volumn 22, Issue 1, 2016, Pages 54-60

  Noguchi, Masanori ^a   Matsumoto, Kazumasa ^b   Uemura, Hirotsugu ^c   Arai, Gaku ^d   Eto, Masatoshi ^e   Naito, Seiji ^f   Ohyama, Chikara ^g   Nasu, Yasutomo ^h   Tanaka, Masatoshi ⁱ   Moriya, Fukuko ^a   Suekane, Shigetaka ^a   Matsueda, Satoko ^a   Komatsu, Nobukazu ^a   Sasada, Tetsuro ^a   Yamada, Akira ^a   Kakuma, Tatsuyuki ^a   Itoh, Kyogo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d DOKKYO MEDICAL UNIVERSITY   (Japan)

^e KUMAMOTO UNIVERSITY   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

^g HIROSAKI UNIVERSITY   (Japan)

^h OKAYAMA UNIVERSITY   (Japan)

ⁱ FUKUOKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; HLA ANTIGEN; IFOSFAMIDE; IMMUNOGLOBULIN G; METHOTREXATE; PEPTIDE VACCINE; PLATINUM COMPLEX; VINBLASTINE; ANTINEOPLASTIC AGENT; CANCER VACCINE; PLATINUM; SUBUNIT VACCINE;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ANTIBODY TITER; ARTICLE; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEMATURIA; HUMAN; HYPOALBUMINEMIA; HYPONATREMIA; IMMUNE RESPONSE; INJECTION SITE REACTION; LOSS OF APPETITE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; URINARY TRACT OBSTRUCTION; VACCINATION; CLINICAL TRIAL; DISEASE COURSE; DRUG RESISTANCE; IMMUNOLOGY; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RETREATMENT; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PLATINUM; RETREATMENT; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; VACCINES, SUBUNIT;

EID: 84954493535     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1265     Document Type: Article

References (22)

1. Loehrer PJ Sr, Elinhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methorexate, vinblastine, cisplatin, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066-73.
2. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methorexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinatinal, multicenter, phase III study. J Clin Oncol 2000;18:3068-77.
3. Carballido EM, Rosenberg JE. Optimal treatment for metastatic bladder cancer. Curr Oncol Rep 2014;16:404.
4. Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urotherial tract. J Clin Oncol 2009;27:4454-61.
5. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Eng J Med 2012;366:2443-54.
6. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Eng J Med 2012;366:2455-65.
7. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014;515:558-62.
8. Rosenberg SA. Anew era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999;10:281-7.
9. Sasada T, Yamada A, Noguchi M, Itoh K. Personalized peptide vaccine for treatment of advanced cancer. Curr Med Chem 2014;21:2332-45.
10. Noguchi M, Sasada T, Itoh K. Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother 2013;62:919-29.
11. Matsumoto K, Noguchi M, Satoh T, Tabata K, Fujita T, Iwamura M, et al. A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin, and cisplatin. BJU Int 2011;108:831-8.
12. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
13. Komatsu N, Shichijo S, Nakagawa M, Itoh K. New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Cin Lab Invest 2004;64:1-11.
14. Yoshiyama K, Terazaki Y, Matsueda S, Shichijo S, Noguchi M, Yamada A, et al. Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol 2012;24:795-801.
15. Anderson JR, Cain KC, Gelber RD. Analyssis of survival by tumor response. J Clin Oncol 1983;1:710-19.
16. Nishiyama T, Tachibana M, Horiguchi Y, Nakamura K, Ikeda Y, Takesako K, et al. Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide. Clin Cancer Res 2001;7:23-31.
17. Sharma P, Bajorin DF, Jungbluth AA, Herr H, Old LJ, Gnjatic S. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BSG and GM-CSF. J Immunother 2008;31:849-57.
18. Obara W, Ohsawa R, Kanehira M, Takata R, Tsunoda T, Yoshida K, et al. Cancer peptide vaccine therapy developed from oncoantigens identified through genomic-wide expression profile analysis for bladder cancer. Jpn J Clin Oncol 2012;42:591-600.
19. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients withmetastatic melanoma. N Engl J Med 2010;363:711-23.
20. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
21. Noguchi M, Yao A, Harada M, Nakashima O, Komohara Y, Yamada S, et al. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate 2007;67:933-42.
22. Cherny NI, Abernethy PA, Strasser F, Sapir R, Currow D, Zafar Y. Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systemic review. J Clin Oncol 2009;27:5476-86.